Condition: Cognitive Impairment · Dementia · Sponsor: Azienda Usl di Bologna
The goal of this observational study is to investigate the frequency and the possible pathogenic role of neuronal synaptic antibodies (NSAb) in patients with cognitive impairment (CI). The main questions it aims to answer are: 1. the frequency and associated features of NSAb in patients with CI and the usefulness of a clinical score in improving autoimmune dementia (AID) diagnosis; 2. the clinical significance of NSAb in patients with CI not fulfilling the autoimmune encephalitis (AE) criteria and serum NSAb (NSAb-pos-CI); 3. the impact of blood-brain-barrier (BBB) dysfunction on their pathogenicity.
This description comes directly from the study's public registry record.
Maria Pia Giannoccaro, Dr. · +390514966112 · mariapia.giannoccaro@ausl.bologna.it
Always discuss trial participation with your own doctor first.
| IRCCS Istituto delle Scienze Neurologiche di Bologna | Bologna, Bologna, Italy | Recruiting |
| Istituto Auxologico Italiano IRCCS | Milan, Milano, Italy | Recruiting |
| Fondazione IRCCS Istituto Neurologico Carlo Besta | Milan, Milano, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06321588